DC based Neoantigen Cancer Vaccine Development Solution

Personalized DC-Based Neoantigen Cancer Vaccine Development

Creative Biolabs is a recognized leader in the field of cancer immunotherapy, providing a sophisticated, end-to-end platform for the development of Personalized Dendritic Cell (DC) Based Neoantigen Cancer Vaccines. By combining high-resolution multi-omics profiling with advanced expertise in DC engineering, we offer customized solutions that bridge the gap between bioinformatics prediction and clinical-grade immunogenicity. Our services support global researchers in overcoming the challenges of tumor heterogeneity and immune evasion.

Harnessing DCs for Next-Generation Neoantigen Vaccines

The Engine of Antitumor Immunity

Dendritic cells (DCs) are the central orchestrators of the immune system. In the context of cancer vaccines, DC-based neoantigen platforms offer a distinct advantage: they don't just deliver antigens; they actively process and present them via both MHC-I and MHC-II pathways, ensuring robust priming of both CD8+ and CD4+ T cell responses. This dual activation is critical for overcoming the immunosuppressive tumor microenvironment.

Why Choose DC-Based Strategies?
Unlike direct peptide or mRNA injection, DC vaccines allow for precise control over antigen loading, maturation state, and co-stimulatory molecule expression before administration, significantly enhancing the "potency" of the immune signal.

Core Preclinical Challenges We Address:
Reducing false positives in neoantigen prediction via immunopeptidomics.
Optimizing the DC maturation cocktail (GM-CSF, IL-4, TLR agonists).
Achieving high-efficiency antigen loading (mRNA Electroporation vs. Peptide Pulsing).
Quantifying antigen-specific T cell activation in vitro and in vivo.

Why DC-Based Carriers Outperform Traditional Vaccines?

Key Comparison	Traditional Vaccines (Direct Injection)	DC-Based Neoantigen Vaccines
Antigen Presentation Efficiency	Passive uptake; susceptible to degradation.	Active, high-efficiency MHC loading ex vivo.
T-cell Activation Specificity	Broad activation; risk of "bystander" effects.	Precise targeting of tumor neoepitopes.
Dual Activation (CD4/CD8)	Often biased towards MHC class II.	Optimized cross-presentation for potent killing.
Potency Control	Unpredictable metabolic stability.	Fully customizable maturation state (Co-stimulatory signal).

End-to-End DC-Neoantigen Vaccine Service Modules

Project Design & Sample Strategy

Strategic project planning and sample processing for optimal starting materials.

Evaluation of cancer indications and sample availability analysis.
Customized sample strategies (Tumor tissue, PBMC, Leukapheresis).
HLA typing strategy and drugability path planning for preclinical or IND.
Risk identification and preclinical timeline optimization.

Neoantigen Discovery & Validation

High-precision multi-omics profiling integrated with physical validation.

Next-generation sequencing (WES/WGS) for somatic mutation identification.
RNA-seq verification to confirm the transcription of mutations.
Bioinformatics prioritization based on HLA binding and immunogenicity.
Validation: HLA-ligandome LC-MS/MS to verify actual presentation.

Antigen Production & DC Engineering

High-quality antigen load synthesis and specialized vehicle preparation.

Synthesis of SLP pools or neoantigen-encoding mRNA.
Construction of DNA or viral vectors (LV/AAV) for unique delivery.
CD14+ monocyte enrichment and controlled induction into DCs.
"Super-DC" maturation matrix using TLR agonists and cytokines.

Antigen Loading & Vaccine Construction

Optimizing parameters for both MHC-I and MHC-II pathways.

Parameter screening for mRNA electroporation and stability monitoring.
Condition optimization for multi-epitope synthetic peptide pulsing.
Formulation development with immunological adjuvants.
QC of loading efficiency and MHC-peptide complex stability.

Comprehensive Potency Evaluation

Rigorous multi-level assessment of the induced antitumor response.

In vitro DC-T co-culture assays, ELISpot, and ICS profiling.
Antigen-specific T cell proliferation and cytotoxic killing assays.
Syngeneic or humanized tumor models for in vivo POC.
TIL profiling, survival analysis, and cytokine monitoring.

QC & IND-Enabling Support

Provision of comprehensive data packages for translation.

Purity, viability, and sterility testing panels for cell products.
Establishment of MOA-based potency assurance strategies.
IND-enabling CMC support and pre-GMP process documentation.
Safety screening including toxicology and pathology.

Optimized Preclinical DC-Neoantigen Vaccine Development Workflow

Phase 1 — Neoepitope Identification & Multi-Omics Profiling

We perform integrated multi-omics analysis using Whole Exome Sequencing (WES) and RNA-seq on tumor and normal tissue samples. This stage focuses on identifying tumor-specific somatic mutations and verifying their actual expression levels.

Phase 2 — Bioinformatics Selection & Physical Validation

Candidate neoantigens are prioritized using advanced algorithms for HLA binding affinity and immunogenicity scoring. We employ LC-MS/MS immunopeptidomics to physically identify peptides naturally presented by the MHC molecules.

Phase 3 — Professional DC Engineering & Maturation

Isolation of high-purity CD14+ monocytes followed by induction into mature Dendritic Cells. We utilize proprietary maturation matrices (TLR agonists and cytokines) to maximize co-stimulatory markers CD80/83/86.

Phase 4 — Precision Antigen Loading & Vaccine Assembly

Loading the neoantigen cargo via mRNA electroporation for endogenous synthesis or SLP pulsing. Our protocols ensure optimal cross-presentation pathways are triggered for coordinated CD4+/CD8+ responses.

Phase 5 — Comprehensive Potency & Efficacy Validation

Final products undergo functional testing, including ELISpot assays for IFN-γ and in vivo efficacy studies using syngeneic or humanized models to confirm therapeutic durability and tumor regression.

Enabling Technologies for High-Potency DC Vaccines

Optimized DC Maturation Matrix

Utilizing specialized Toll-like receptor (TLR) agonists and cytokine cocktails to induce potent DC maturation. This approach ensures high IL-12 secretion and enhanced lymph node homing for superior priming.

MHC Ligandome Mass Spectrometry

A sophisticated immunopeptidomics platform using Orbitrap LC-MS/MS to physically identify peptides bound to MHC molecules, reducing false-positive rates by up to 60%.

Synergistic Cross-Presentation Strategy

Advanced loading protocols ensuring neoantigens are funneled into both MHC class I and II pathways, stimulating a coordinated response from both CD4+ and CD8+ T cells.

Why Choose Creative Biolabs?

Extensive Preclinical Expertise

Leveraging a decade of immunotherapy research, our scientists possess deep insights into DC biology and tumor immunology.

Advanced Multi-Omics Integration

Our platform integrates NGS-based discovery with mass spectrometry validation, providing higher accuracy in ranking.

Customizable Service Modules

From specific maturation cocktails to unique loading strategies, we offer fully flexible modules tailored to your goals.

End-to-End Reliability

We provide complete traceability and rigorous QC for every step, offering a streamlined path to final efficacy reports.

Research Insight: DC-Neoantigen Vaccines for Advanced Lung Cancer

Key Findings from Preclinical & Pilot Studies

Personalized neoantigen-pulsed DC vaccines have shown remarkable potential in aggressive malignancies like lung cancer, which is characterized by a high tumor mutation burden (TMB).

High Immunogenicity: Studies utilizing WES and RNA-seq have identified a median of 312 somatic mutations per patient. Neoantigen-pulsed DCs successfully elicited specific T-cell responses in 100% of evaluable subjects.
T Cell Repertoire Expansion: High-throughput TCR sequencing revealed a 1000-fold increase in specific T-cell clones after vaccine exposure, indicating successful "priming."
Synergy with Checkpoint Inhibitors: In anti-PD-1 resistant models, DC-based vaccines re-sensitized the immune system, leading to target lesion regression.

Clinical and immune responses to personalized Neo-DCVac therapy in patient 1 with metastatic lung adenocarcinoma.

Fig.1 Clinical and immune responses of personalized Neo-DCVac in metastatic lung adenocarcinoma patient 1.^1.2

FAQs Regarding DC-Neoantigen Services

mRNA electroporation allows the DC to endogenously synthesize the full neoantigen protein, which is then naturally processed and presented via both MHC class I and II pathways. This often leads to more sustained antigen presentation and avoids the rapid "wash-out" associated with short peptides.

Yes. We specialize in preparing Bone Marrow-Derived DCs (BMDCs) from mouse models for in vivo Proof-of-Concept (POC) studies. This includes syngeneic models or humanized mouse models for testing human-specific neoantigen candidates.

Bioinformatics algorithms often have a high false-positive rate. By adding in vitro T cell activation assays and mass spectrometry-based immunopeptidomics, we ensure that only biologically relevant and truly presented epitopes are included in your vaccine construct.

For preclinical characterization, we routinely use flow cytometry to detect CD11c, HLA-DR, CD80, CD83, and CD86. High levels of these markers indicate effective maturation and a high capacity for T cell co-stimulation.

Absolutely. Many of our clients explore the synergistic effects of DC vaccines and immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) in in vivo models. We can assist in designing dosing schedules and evaluating endpoints like tumor regression and TIL density.